UniProt ID | CLK4_HUMAN | |
---|---|---|
UniProt AC | Q9HAZ1 | |
Protein Name | Dual specificity protein kinase CLK4 | |
Gene Name | CLK4 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 481 | |
Subcellular Localization | Nucleus. | |
Protein Description | Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex and may be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing. Phosphorylates SRSF1 and SRSF3. Required for the regulation of alternative splicing of MAPT/TAU. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells.. | |
Protein Sequence | MRHSKRTHCPDWDSRESWGHESYRGSHKRKRRSHSSTQENRHCKPHHQFKESDCHYLEARSLNERDYRDRRYVDEYRNDYCEGYVPRHYHRDIESGYRIHCSKSSVRSRRSSPKRKRNRHCSSHQSRSKSHRRKRSRSIEDDEEGHLICQSGDVLRARYEIVDTLGEGAFGKVVECIDHGMDGMHVAVKIVKNVGRYREAARSEIQVLEHLNSTDPNSVFRCVQMLEWFDHHGHVCIVFELLGLSTYDFIKENSFLPFQIDHIRQMAYQICQSINFLHHNKLTHTDLKPENILFVKSDYVVKYNSKMKRDERTLKNTDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFQTHDSKEHLAMMERILGPIPQHMIQKTRKRKYFHHNQLDWDEHSSAGRYVRRRCKPLKEFMLCHDEEHEKLFDLVRRMLEYDPTQRITLDEALQHPFFDLLKKK | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
4 | Phosphorylation | ----MRHSKRTHCPD ----CCCCCCCCCCC | 17.30 | 30576142 | |
7 | Phosphorylation | -MRHSKRTHCPDWDS -CCCCCCCCCCCCCC | 31.41 | 30576142 | |
14 | Phosphorylation | THCPDWDSRESWGHE CCCCCCCCCCCCCCC | 33.42 | 23927012 | |
17 | Phosphorylation | PDWDSRESWGHESYR CCCCCCCCCCCCCCC | 36.93 | 23927012 | |
22 | Phosphorylation | RESWGHESYRGSHKR CCCCCCCCCCCCCCC | 17.92 | 23927012 | |
33 | Phosphorylation | SHKRKRRSHSSTQEN CCCCCCCCCCCCHHC | 31.58 | 30576142 | |
35 | Phosphorylation | KRKRRSHSSTQENRH CCCCCCCCCCHHCCC | 36.01 | 30576142 | |
36 | Phosphorylation | RKRRSHSSTQENRHC CCCCCCCCCHHCCCC | 28.78 | 30576142 | |
37 | Phosphorylation | KRRSHSSTQENRHCK CCCCCCCCHHCCCCC | 42.81 | 30576142 | |
72 | Phosphorylation | RDYRDRRYVDEYRND CHHHCHHHHHHHHCC | 17.10 | 27642862 | |
76 | Phosphorylation | DRRYVDEYRNDYCEG CHHHHHHHHCCCCCC | 15.39 | 27642862 | |
80 | Phosphorylation | VDEYRNDYCEGYVPR HHHHHCCCCCCCCCC | 8.92 | 29978859 | |
95 | Phosphorylation | HYHRDIESGYRIHCS CCCCCCCCCCEEEEC | 41.27 | 27251275 | |
102 | Phosphorylation | SGYRIHCSKSSVRSR CCCEEEECHHHHHCC | 22.78 | 27732954 | |
104 | Phosphorylation | YRIHCSKSSVRSRRS CEEEECHHHHHCCCC | 20.12 | 27732954 | |
105 | Phosphorylation | RIHCSKSSVRSRRSS EEEECHHHHHCCCCC | 25.86 | 24719451 | |
108 | Phosphorylation | CSKSSVRSRRSSPKR ECHHHHHCCCCCCCH | 29.86 | 30576142 | |
111 | Phosphorylation | SSVRSRRSSPKRKRN HHHHCCCCCCCHHHC | 50.29 | 30576142 | |
112 | Phosphorylation | SVRSRRSSPKRKRNR HHHCCCCCCCHHHCC | 32.40 | 30576142 | |
122 | Phosphorylation | RKRNRHCSSHQSRSK HHHCCCCCCHHHHCH | 25.40 | - | |
123 | Phosphorylation | KRNRHCSSHQSRSKS HHCCCCCCHHHHCHH | 30.82 | - | |
126 | Phosphorylation | RHCSSHQSRSKSHRR CCCCCHHHHCHHHHH | 32.85 | - | |
128 | Phosphorylation | CSSHQSRSKSHRRKR CCCHHHHCHHHHHHH | 43.70 | - | |
136 | Phosphorylation | KSHRRKRSRSIEDDE HHHHHHHCCCCCCCC | 33.15 | 23927012 | |
138 | Phosphorylation | HRRKRSRSIEDDEEG HHHHHCCCCCCCCCC | 31.41 | 22167270 | |
151 | Phosphorylation | EGHLICQSGDVLRAR CCEEEECCCCHHHHE | 32.33 | 33259812 | |
189 | Sumoylation | DGMHVAVKIVKNVGR CCHHHHHHHHHHHHH | 31.85 | - | |
189 | Ubiquitination | DGMHVAVKIVKNVGR CCHHHHHHHHHHHHH | 31.85 | - | |
189 | Sumoylation | DGMHVAVKIVKNVGR CCHHHHHHHHHHHHH | 31.85 | - | |
296 | Ubiquitination | PENILFVKSDYVVKY HHHEEEECCCEEEEC | 30.21 | 29967540 | |
302 | Ubiquitination | VKSDYVVKYNSKMKR ECCCEEEECCCCCCC | 28.77 | 29967540 | |
315 | Ubiquitination | KRDERTLKNTDIKVV CCCCCHHCCCCEEEE | 58.13 | 29967540 | |
326 | Phosphorylation | IKVVDFGSATYDDEH EEEEEECCCCCCCCC | 19.89 | 29255136 | |
328 | Phosphorylation | VVDFGSATYDDEHHS EEEECCCCCCCCCCC | 29.22 | 29255136 | |
329 | Phosphorylation | VDFGSATYDDEHHST EEECCCCCCCCCCCE | 22.55 | 29255136 | |
335 | Phosphorylation | TYDDEHHSTLVSTRH CCCCCCCCEEEECCC | 25.91 | 30266825 | |
336 | Phosphorylation | YDDEHHSTLVSTRHY CCCCCCCEEEECCCC | 27.16 | 30266825 | |
339 | Phosphorylation | EHHSTLVSTRHYRAP CCCCEEEECCCCCCC | 23.88 | 29255136 | |
340 | Phosphorylation | HHSTLVSTRHYRAPE CCCEEEECCCCCCCH | 17.62 | 23401153 | |
343 | Phosphorylation | TLVSTRHYRAPEVIL EEEECCCCCCCHHHH | 12.74 | 30576142 | |
479 | Ubiquitination | HPFFDLLKKK----- CHHHHHHHCC----- | 66.85 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of CLK4_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of CLK4_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CLK4_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
CLASR_HUMAN | CLASRP | physical | 12169693 | |
RN181_HUMAN | RNF181 | physical | 21988832 | |
SRRM2_HUMAN | SRRM2 | physical | 23602568 | |
SAHH3_HUMAN | AHCYL2 | physical | 23602568 | |
RASL2_HUMAN | RASA4 | physical | 23602568 | |
TCP4_HUMAN | SUB1 | physical | 23602568 | |
KR107_HUMAN | KRTAP10-7 | physical | 25416956 | |
KR109_HUMAN | KRTAP10-9 | physical | 25416956 | |
KR108_HUMAN | KRTAP10-8 | physical | 25416956 | |
KR103_HUMAN | KRTAP10-3 | physical | 25416956 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-136 AND SER-138, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-136 AND SER-138, ANDMASS SPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-136 AND SER-138, ANDMASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-138, AND MASSSPECTROMETRY. |